Evolus’ Jeuveau (prabotulinumtoxinA-xvfs) Receives FDA Approval for Moderate-to-Severe Glabellar Lines in Adults

 Evolus’ Jeuveau (prabotulinumtoxinA-xvfs) Receives FDA Approval for Moderate-to-Severe Glabellar Lines in Adults

Evolus’ Jeuveau (prabotulinumtoxinA-xvfs) Receives FDA Approval for Moderate-to-Severe Glabellar Lines in Adults

Shots:

  • The approval is based on four P-III trials including two (EV-001 & EV-002) US trials and European & Canadian i.e TRANSPARENCY study results assessing Jeuveau vs PBO & Botox respectively in 2,100 patients with glabellar lines due to corrugator or procerus muscle activity in adults
  • The TRANSPARENCY study collectively resulted in meeting 1EPs (67.5%, 70.4% vs 1.2%, 1.3%) & demonstrated safe and effective results
  • Jeuveau (prabotulinumtoxinA-xvfs) injection is a neurotoxin, Type A formulation of 900 kDa purified botulinum toxin developed using Hi-Pure technology with its expected marketing in H1’19

Click here to read full press release/ article | Ref: Globe Newswire | Image: Evolus

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post